July 29, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Company Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
 Eisai

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. 

Company Headquarters 4-6-10 Koishikawa, Bunkyo-ku,Tokyo 112-8088, JAPAN 
Company Telephone +81-3-3817-3724 
Company Stock Code - TSE
4523 
 CompanyStock Price - TSE   
Company Stock Code - U.S.
ESALY 
 CompanyStock Price - U.S.
Company CEO Haruo Naito 
Company Sector Alternative Energy 
Company Industries Pharmaceutical
Company Established 1941 
Company Listed 1961 
Company Homepage www.eisai.com
Company Annual Report
Company CSR Report


Headline News for Eisai  

No records were found in the Headlines

 


Press Releases for Eisai  

Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy (Jul 3, 2014)

Eisai to Launch First Chocola BB Brand Product "Chocola BB Royal Drink" in China (Jul 2, 2014)

Eisai Submits First Marketing Authorization Application for Anticancer Agent Lenvatinib in Japan (Jun 27, 2014)

Phase Iii Trial of Antiepileptic Drug Fycompa (Perampanel) Meets Primary Endpoints (Jun 17, 2014)

Eisai Honored with Prestigious 'UCL Enterprise Partner Of The Year 2014' Award By University College London (UCL) (May 30, 2014)

Antiemetic Agent Aloxi Approved for Children by the U.S. FDA (May 29, 2014)

Eisai Receives Positive Opinion from EMA's CHMP on Expanding (May 27, 2014)

Eisai to Launch Chocola BB Sparkling Salty Natsumikan Flavor (May 27, 2014)

Eisai's R&D Subsidiary Kan Research Institute Commences Full-Scale Operation at New Facility (May 26, 2014)

Eisai to Present New Research on Oncology Products and Pipeline at 50th Asco Annual Meeting (May 15, 2014)

Eisai Resubmits Antiepileptic Drug Fycompa to German Federal Joint Committee for Additional Benefit Assessment (May 12, 2014)

Eisai Launches New Comprehensive Information Website about Neglected Tropical Diseases and Elimination Initiatives (Apr 24, 2014)

Eisai CEO Haruo Naito Appointed Knight Commander of British Empire (Apr 15, 2014)

Eisai Launches New Energy Drink "Joma" (Apr 7, 2014)

Notice Concerning Voluntary Adoption of International Financial Reporting Standards (IFRS) (Mar 25, 2014)

Eisai Enters Collaboration with Liverpool School of Tropical Medicine and University of Liverpool to Discover Novel Anti-Wolbachia Targeted Anti-Filarial Drugs (Mar 20, 2014)

Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan (Feb 13, 2014)

Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer (Feb 3, 2014)

Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan (Feb 3, 2014)

Eisai Announces Launch of New "Crystal Veil Mask Bokin 24 Mint" Face Mask Spray Containing Long-acting Antimicrobial Agent Etak (Jan 22, 2014)

Previous... More...


 

Actions

• Register for News Alerts about Eisai here

• Back to Previous Page

• View more Company Profile Listings

 
 
Photo News

Suprema Launches Fingerprint Scanner SDK for Android
More >> 
Annual Reports

  More >>    
CSR Reports

  More >> 


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)